Floatz Rating
C37/100
Confidence
Indicative
Sponsor
Accent Therapeutics
Modality
Small molecule
Development Phase
Phase 1
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
28Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06625515CT.gov First-in-Human Study of ATX-559, an Oral Inhibitor of DHX9, in Patients With Advanced or Metastatic Solid Tumors, and Molecularly Defined Cancers | — | Terminated | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
65Moderate confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Endometrial Carcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Atx-559 (this asset) | Accent Therapeutics | P1 | C · 37 |
| Adriamycin | AstraZeneca | P3 | BB |
| Indocyanine Green | Istanbul University | P4 | BB |
| Olaparib | Qilu Pharmaceutical Co., Ltd. | P4 | B |
| Palbociclib | University Medical Center Groningen | P4 | B |
| Carboplatin | Qilu Pharmaceutical Co., Ltd. | P3 | B |
| Docetaxel | Merck Sharp & Dohme LLC | P3 | B |
| Rilvegostomig | AstraZeneca | P3 | B |
| Cyclophosphamide | Sutro Biopharma, Inc. | P3 | B |
+42 more in the Endometrial Carcinoma cohort
Other indications for Atx-559
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Breast Cancer | — | P1 | CC · 43 |
| Rectum Adenocarcinoma | — | P1 | C · 39 |
| Metastatic Malignant Neoplasm In The Colon | — | P1 | C · 37 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Atx-559 in Endometrial Carcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 14, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/atx-559-endometrial-carcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →